Actively Recruiting
First In Human Study of CX-801 in Advanced Solid Tumors
Led by CytomX Therapeutics · Updated on 2026-03-24
121
Participants Needed
2
Research Sites
252 weeks
Total Duration
On this page
Sponsors
C
CytomX Therapeutics
Lead Sponsor
M
Merck Sharp & Dohme LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this first-in-human study, CTMX-801-101, is to characterize the safety, tolerability, and antitumor activity of CX-801 as monotherapy and in combination with pembrolizumab in adult participants with advanced solid tumors.
CONDITIONS
Official Title
First In Human Study of CX-801 in Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Measurable disease per RECIST v1.1
- Consent to fresh biopsy or, if medically contraindicated, recent (within 6 months) archival tumor tissue
- Adequate organ function
- Additional inclusion criteria may apply
You will not qualify if you...
- Recent history (within last 2 years) of localized cancers not related to the current cancer being treated
- Known active central nervous system (CNS) involvement by malignancy
- Prior PD-1/PD-(L)1 inhibitor treatment stopped due to grade 3 or higher immune related adverse event
- Systemic anticancer treatment within 4 weeks or 5 half lives prior to first dose of study treatment
- Investigational drug or device within 4 weeks prior to first dose of study treatment
- Radiation within 2 weeks prior to first dose of study treatment
- Serious concurrent illness
- Pregnant or breast feeding
- Additional exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University of Pittsburgh Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
2
SCRI Oncology Partners
Nashville, Tennessee, United States, 37203
Actively Recruiting
Research Team
K
Karen Deane
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here